Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|October 7, 2024

Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial

Author(s)Fred Saad, CQ, MD, FRCS, FCAHS

Key Takeaways

Chemotherapy, particularly docetaxel, significantly influences the adverse event profile, with common side effects including neutropenia, fatigue, and diarrhea.
The ARASENS trial findings align with previous studies, confirming the consistency of observed adverse effects with clinical practice.
Effective monitoring and management of adverse events are crucial for optimizing patient outcomes and maintaining quality of life during chemotherapy.

SHOW MORE

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how the inclusion of chemotherapy, particularly docetaxel, in combination therapies for metastatic prostate cancer alters the adverse event profile, noting that while the ARASENS trial found adverse effects to be largely consistent with previous docetaxel studies, they consider whether this aligns with observations in clinical practice.

Episodes in this series

1 KOL is featured in this series.

EP. 1 Therapeutic Combination Therapies for Metastatic Prostate Cancer

1 KOL is featured in this series.

EP. 2 Patient-Centered Approach to Use of Chemotherapy in Metastatic Prostate Cancer

1 KOL is featured in this series.

EP. 3 Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial

1 KOL is featured in this series.

EP. 4 Patient Selection for Chemotherapy-Based Combination Regimens in Metastatic Prostate Cancer

1 KOL is featured in this series.

EP. 5 Clinical Perspectives from the ARANOTE Trial in Metastatic Hormone-Sensitive Prostate Cancer

1 KOL is featured in this series.

EP. 6 Key Findings From ARANOTE: Darolutamide Plus ADT in mHSPC

1 KOL is featured in this series.

EP. 7 Insights From ARANOTE and Clinical Practice

1 KOL is featured in this series.

EP. 8 The Evolving Role of Radium-223 in mCRPC and the Impact of Combination Therapies

1 KOL is featured in this series.

EP. 9 Radium-223 and Enzalutamide: Game-Changing PEACE III Phase 3 Data in mCRPC

1 KOL is featured in this series.

EP. 10 Genetic Testing in Metastatic Prostate Cancer: Key Insights on Germline and Somatic Mutations

1 KOL is featured in this series.

EP. 11 PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies

1 KOL is featured in this series.

EP. 12 Key Trials on PARP Inhibitor Combinations in Metastatic Prostate Cancer: Efficacy and Future Considerations

Video Content above is prompted by the following:

How does inclusion of chemotherapy affect the adverse event profile? In the ARASENS trial (NCT02799602), authors concluded that many of the adverse effects were consistent with those observed in previous studies with docetaxel. Is this consistent with what you see in clinical practice?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

Scott T. Tagawa, MD, MS, FACP, FASCO; Anusha Madadi, MD

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Jeremie Calais, MD, PhD; Jason Zhu, MD

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Nasfat Shehadeh, MD; Jeremie Calais, MD, PhD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

MRI, myths, and precision: Stacy Loeb, MD, discusses modern prostate cancer screening

Sean P. Collins, MD, PhD, outlines the impact of rectal spacers for men with prostate cancer

Suzanne Merrill, MD, on integrating ICIs into clinical practice for NMIBC

Dual targeting of PAM and AR pathways yields encouraging results in mCRPC

Adverse Event Considerations for Prostate Cancer Treatment With Enzalutamide

© 2025 MJH Life Sciences^®

All rights reserved.